Hepatitis C Treatment
|
|
- Sherilyn Clarke
- 5 years ago
- Views:
Transcription
1 Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l S c i e n c e s I m a m K h o m e i n i H o s p i t a l
2 Who should be considered for HCV treatment? All treatment-naïve HCV-RNA positive patients baseline ALT level whatever their Compensated chronic liver disease related to HCV Willing to be treated Have no contraindication to pegylated IFN-a or ribavirin
3 Who should be considered for HCV treatment? All treatment-naïve HCV-RNA positive patients baseline ALT level whatever their compensated chronic liver disease related to HCV willing to be treated have no contraindication to pegylated IFN-a or ribavirin
4 Assessment of liver disease severity Liver disease severity should be assessed prior to therapy (Identifying fibrosis and cirrhosis) Clinical Liver biopsy Transient elastography (Fibroscan) Panels of biomarkers of fibrosis (Fibrotest) To determine: likelihood of responding to therapy post-treatment prognosis surveillance for HCC is required in cirrhotic patients
5 Who should be considered for HCV treatment? All treatment-naïve HCV-RNA positive patients baseline ALT level whatever their compensated chronic liver disease related to HCV willing to be treated have no contraindication to pegylated IFN-a or ribavirin
6 Search systematically for other causes of liver disease The causal relationship between HCV infection and liver disease must be established. Other disease must be ruled out. HIV and/or other hepatotropic viruses Alcoholic liver disease Autoimmune liver disease metabolic liver disease with steatosis or steatohepatitis pre-existing thyroid disease
7 Who should be considered for HCV treatment? All treatment-naïve HCV-RNA positive patients baseline ALT level whatever their compensated chronic liver disease related to HCV willing to be treated have no contraindication to pegylated IFN-a or ribavirin
8 Absolute contra-indication for HCV therapy Uncontrolled Depression Uncontrolled Psychosis Uncontrolled Epilepsy Uncontrolled autoimmune diseases Cirrhosis Child B7 or more Pregnant women or couples unwilling to comply with adequate contraception Severe concurrent medical disease (poorly controlled HTN, heart failure, diabetes, and COPD)
9 Relative contraindications for HCV therapy Abnormal hematological indices (Hb <13 for men and <12 for women, PMN <1500, PLT <90,000) Creatinine >1.5 mg/dl Significant coronary heart disease Untreated thyroid diseases
10 Power of recommendation for HCV treatment! Treatment should be initiated promptly in patients with advanced fibrosis (stage 3-4/6) Treatment strongly considered in patients with moderate fibrosis (stage 2/6) Treatment individualized in patients with mild fibrosis (stage 0-1/6) particularly with longstanding infection Individualized by risk / benefit balance related to therapy, consider new drugs and life expectancy of patient
11 EASL 2011 HCV Guidelines: PegIFN/RBV Regimens Genotype 1/4 PegIFN alfa-2a PegIFN alfa-2b PegIFN dose (weekly) 180 µg 1.5 µg/kg RBV dose (daily) 15 mg/kg 15 mg/kg Planned duration* 48 wks 48 wks Genotype 2/3 PegIFN alfa-2a PegIFN alfa-2b PegIFN dose (weekly) 180 µg 1.5 µg/kg RBV dose (daily) 800 mg 800 mg If low responsiveness anticipated 15 mg/kg 15 mg/kg Planned duration 24 wks 24 wks *24 wks of therapy can be considered in patients with low HCV RNA (< 400, ,000 IU/mL) who achieve RVR wks can be considered in patients who achieve RVR. Craxi A, et al. J Hepatology. 2011
12 What are the endpoints in HCV therapy? The goal of therapy is to eradicate HCV infection. (virologic cure ) The endpoints are defined by virologicl response. Virological responses is defined by negative HCV-RNA PCR by sensitive PCR assay. RVR rapid virological response at week 4 EVR early virological response at week 12 DVR delay virological response at week 24 Intermediate on-treatment endpoints Assess likelihood of receiving final endpoint (SVR) SVR sustained virological response at week 24 after stopping therapy
13 What the endpoints mean in HCV therapy?
14 EASL: Response-Guided Therapy in Patients With Genotype 1 HCV RNA Wk Neg (RVR) Pos Pos < 2 log drop (NR) Stop Tx Pos (PR) Pos > 2 log drop Neg (EVR) Neg (DVR) 24 wks of therapy, only if LVL* at baseline *HCV RNA < 400, ,000 IU/mL 48 wks of therapy 72 wks of therapy Craxi A, et al. J Hepatol. 2011
15 EASL: Response-Guided Therapy in Patients With Genotype 2/3 HCV RNA Wk Neg (RVR) Pos Pos < 2 log drop or pos at Wk 24 Stop Tx Risk factors (fibrosis, IR) Pos > 2 log drop but neg thereafter (DVR) Neg (EVR) wks of therapy* 24 wks of therapy 48 wks of therapy *Marginally less effective due to higher relapse rates, especially for genotype 3 with high HCV RNA. Craxi A, et al. J Hepatol. 2011
16 HCV RNA (log 10 IU/mL) Patterns of Virologic Non-Response PegIFN alfa and RBV NullResponse* Partial Non-Response* 3 2 Relapse 1 Undetectable RVR EVR ETR SVR Wks After Start of Therapy *Subset of Nonresponse Ghany MG, et al. Hepatology. 2009;49: Reprinted with permission from the AASLD.
17 Benefits of Sticking to HCV treatment Guidelines Increase viral eradication (higher SVR) Reduce unnecessary exposure to drugs (dose optimization) By shortening therapy in patients likely to achieve SVR without requiring the full duration By terminating therapy early in patients unlikely to achieve SVR Decrease side effect (better tolerance and quality of life)
18 HCV therapy - managing adverse events Importance of keeping patients on treatment: impact on SVR Full treatment ( 80% of dose & duration ) SVR 67% Dose reduction ( < 80% of dose ) SVR 56% Discontinuation ( < 80% of duration ) SVR 7%
19 Better adherence to therapy can be achieved by better management of AEs Anticipating AEs Educating and motivating the patient Initiating appropriate prevention and treatment measures in a timely fashion
20 Severity Appearance of AEs varies over time Flu-like symptoms 3, Duration of interferon therapy (weeks) 1. McHutchison JG, et al. Am J Gastroenterol 2007; 102: 880; 2. Reau N, et al. Am J Gastroenterol 2008; 103: Russo MW & Fried MW. Gastroenterology 2003; 124: 1711; 4. Smith JP. Pharmacotherapy 2008; 28: Kraus MR, et al. World J Gastroenterol 2005; 11: 1769; 6. Fontana RJ, et al. Am J Gastroenterol 2008; 103: 1
21 Severity Appearance of AEs varies over time Flu-like symptoms 3,4 Fatigue Duration of interferon therapy (weeks) 1. McHutchison JG, et al. Am J Gastroenterol 2007; 102: 880; 2. Reau N, et al. Am J Gastroenterol 2008; 103: Russo MW & Fried MW. Gastroenterology 2003; 124: 1711; 4. Smith JP. Pharmacotherapy 2008; 28: Kraus MR, et al. World J Gastroenterol 2005; 11: 1769; 6. Fontana RJ, et al. Am J Gastroenterol 2008; 103: 1
22 Severity Appearance of AEs varies over time Anaemia 1,2 / neutropenia 3 / thrombocytopenia 3 Flu-like symptoms 3,4 Fatigue Duration of interferon therapy (weeks) 1. McHutchison JG, et al. Am J Gastroenterol 2007; 102: 880; 2. Reau N, et al. Am J Gastroenterol 2008; 103: Russo MW & Fried MW. Gastroenterology 2003; 124: 1711; 4. Smith JP. Pharmacotherapy 2008; 28: Kraus MR, et al. World J Gastroenterol 2005; 11: 1769; 6. Fontana RJ, et al. Am J Gastroenterol 2008; 103: 1
23 Severity Appearance of AEs varies over time Anaemia 1,2 / neutropenia 3 / thrombocytopenia 3 Flu-like symptoms 3,4 Fatigue 4 Psychiatric side effects (depression) 5, Duration of interferon therapy (weeks) 1. McHutchison JG, et al. Am J Gastroenterol 2007; 102: 880; 2. Reau N, et al. Am J Gastroenterol 2008; 103: Russo MW & Fried MW. Gastroenterology 2003; 124: 1711; 4. Smith JP. Pharmacotherapy 2008; 28: Kraus MR, et al. World J Gastroenterol 2005; 11: 1769; 6. Fontana RJ, et al. Am J Gastroenterol 2008; 103: 1
24 Potential AEs can be anticipated by proper assessment of patients BASELINE Screen Course of therapy Ghany MG, et al. Hepatology 2009; 49: 1335 Craxi A, et al. J Hepatol 2011; 55: 245
25 Potential AEs can be anticipated by proper assessment of patients Liver failure BASELINE Screen Pre-existing medical problems: - anemia, cytopenia - Thyroid disease (hypo-, hyper-) - Diabetes mellitus, Gout - Renal failure - Active autoimmune disease - Depression, Psychosis, Suicide - Hypertension, Underlying heart disease, CVA - Skin disease, anaphylaxia Pregnancy, Willingness to pregnancy Active addiction Course of therapy Ghany MG, et al. Hepatology 2009; 49: 1335 Craxi A, et al. J Hepatol 2011; 55: 245
26 Potential AEs can be anticipated by proper assessment of patients BASELINE Screen: Underlying heart disease Pre-existing medical problems Depression WEEKS 1, 2 AND 4? Assess: AEs Treatment adherence Laboratory tests: CBC creatinine ALT Course of therapy EVERY 4 WEEKS? Pregnancy testing CBC = Complete blood count ALT = Alanine transaminase Ghany MG, et al. Hepatology 2009; 49: 1335 Craxi A, et al. J Hepatol 2011; 55: 245
27 Potential AEs can be anticipated by proper assessment of patients BASELINE Screen: Underlying heart disease Pre-existing medical problems Depression WEEKS 1, 2 AND 4? Assess: AEs Treatment adherence Laboratory tests: CBC creatinine ALT 48 WEEK INTERVALS Repeat assessments Course of therapy EVERY 4 WEEKS? Pregnancy testing EVERY 12 WEEKS Thyroid function Ghany MG, et al. Hepatology 2009; 49: 1335 Craxi A, et al. J Hepatol 2011; 55: 245
28 Better adherence to therapy can be achieved by better management of AEs Anticipating AEs Educating and motivating the patient Initiating appropriate prevention and treatment measures in a timely fashion
29 Severity Patients should be informed that the appearance of AEs varies over time Anaemia 1,2 / neutropenia 3 / thrombocytopenia 3 Flu-like symptoms 3,4 Fatigue 4 Psychiatric side effects (depression) 5, Duration of interferon therapy (weeks) 1. McHutchison JG, et al. Am J Gastroenterol 2007; 102: 880; 2. Reau N, et al. Am J Gastroenterol 2008; 103: Russo MW & Fried MW. Gastroenterology 2003; 124: 1711; 4. Smith JP. Pharmacotherapy 2008; 28: Kraus MR, et al. World J Gastroenterol 2005; 11: 1769; 6. Fontana RJ, et al. Am J Gastroenterol 2008; 103: 1
30 Side effects that need urgent attention Severe depression, suicidal thoughts Chest pain or difficulty breathing Persistent fever Loss of vision or blurry vision Worsenig of psoriasis Bloody diarrhea Unusual bleeding or bruising Severe abdominal or lower back pain Hepatitis C Support Project Available at
31 Side effects that need urgent attention Severe depression Chest pain or difficulty breathing Persistent fever Loss of vision Patients or should blurry understand vision that side Worsening discontinuation of psoriasis and all are reversible Bloody diarrhoea Unusual bleeding or bruising Severe abdominal or lower back pain effects can be treated effectively to avoid treatment Hepatitis C Support Project Available at
32 Better adherence to therapy can be achieved by better management of AEs Anticipating AEs Educating and motivating the patient Initiating appropriate prevention and treatment measures in a timely fashion
33 Common AEs associated with HCV therapy Flu-like symptoms Fatigue, headache, fever, myalgia and rigors 13 Haematological AEs 1,3,4 Anaemia, neutropenia and thrombocytopenia HCV treatment-associated AEs Dermatological AEs 4 Skin rashes and itching, injection site reactions, hair loss and eye problems Neuropsychiatric symptoms 4 Cognitive impairment, anxiety, depression, irritability, insomnia and psychosis (rare) Gastrointestinal AEs 4 Nausea, diarrhea, weight loss, dehydration, taste changes and mouth sores 1. Fried M, et al. NEJM 2002; 347: 975; 2.Hadziyannis S, et al. Ann Intern Med 2004; 140: 346; 3. Russo and Fried. Gastroenterol 2003; 124:1711; 4. Hepatitis C Support Project Available at
34 Management of flu-like symptoms Advise patients to anticipate symptoms 1 Use analgesics such as paracetamol or ibuprofen 1,2 Get adequate sleep 2 Management of flu-like symptoms Maintain adequate hydration 1,2 Coincide dosing schedule with days off work 1 Dose reductions are not required or recommended 1 1. Russo MW & Fried MW. Gastroenterol 2003; 124: Hepatitis C Support Project Available at
35 Management of gastrointestinal AEs Nausea/anorexia: (2040%) prokinetic or anti-emetic agents (dopamine antagonist or 5HT4 agonist) 1,2 Diarrhea: (1525%) opioid receptor agonist loperamide 1,2 Dehydration: drink plenty of water 2 Management of gastrointestinal AEs Taste changes: drink plenty of water and eat cold food 2 Weight loss: (2030%) reassurance, check glucose and thyroid function 1,2 Oral ulcers: topical anaesthesia or topical steroid 1,2 1. Sulkowski MS, et al. Nat Rev Gastroenterol Hepatol 2001; 8: Hepatitis C Support Project Available at
36 Management of anaemia (1) Common AE resulting from Peg-IFN (bone marrow suppression) and RBV (extravascular haemolysis) 1 Start with normal Hb, correct anemia, if possible Start appropriate dose of RBV ensures the best chance of a cure 2,3 Maintaining RBV dose is essential for preventing relapse, SVR 2,3 Erythropoietin may allow for a higher RBV starting dose with less anemia and higher SVR, 4 but this needs to be confirmed 1. Sulkowski MS, et al. Nat Rev Gastroenterol Hepatol 2001; 8: Reddy K, et al. Clin Gastroenterol Hepatol 2007; 5: Mac Nicholas R & Norris S. Aliment Pharmacol Ther 2010; 31: Shiffman ML, et al. Hepatology 2007; 46: 371
37 Management of anaemia (2) If dose reductions are required, the smallest reduction should be used (200 mg/day) to maintain exposure Reduce dose to 600 mg if: Hgb < 10 g/dl in patients without cardiac factors Return to the original dosing is not recommended Discontinue if: Hgb < 8.5 g/dl in patients without cardiac factors If abnormality is reversed, RBV may be restarted at 600 mg daily and further increased to 800 mg daily at the discretion of the treating physician
38 Management of neutropenia and thrombocytopenia Neutrophils and platelets decrease after initiation of treatment and generally stabilise after 48 weeks No association between severity of neutropenia and the incidence of infection 14 Consider Peg-IFN dose modifications if: Neutrophils < 750/mm 3 Platelets <50 000/mm 3 Once cell counts have recovered, consideration should be given to restoring the dose of Peg-IFN Discontinuation of Peg-IFN rarely required but consider if: Neutrophils < 500/mm 3 When neutrophils >1000/mm 3, Peg-IFN alfa-2a can be restarted initially at 90 g 5 Platelets < /mm 3 1. Cooper CL, et al. Clin Infect Dis 2006; 42: Antonini MG, et al. Infection 2008; 36: Alvarez-Uria G, et al. Dig Dis Sci 2010; 55: Yang JF, et al. Aliment Pharmacol Ther 2009; 29: PEGASYS SPC
39 Management of depression Pre-treatment with a selective serotonin re-uptake inhibitor (SSRI) may prevent drop-out and increase SVR 1,2 Treat with SSRI after the onset of symptoms 3 Management of depression Non-pharmacological strategies, e.g. counselling, family support Treatment interruption may be required for severe cases 1. Raison CL, et al. Aliment Pharmacol Ther 2007; 25: Morasco BJ, et al. J Affect Disord 2007; 103: Kraus MR, et al. Gut 2008; 57: 531
40 Conclusions All patients treated with Peg-IFN and RBV will experience some AEs during therapy Exposure to treatment is a critical determinant of SVR Adherence can be improved through careful pre-treatment assessment and ontreatment management of AEs Only a minority of patients will require significant dose reduction or premature discontinuation if AEs are managed proactively Educating of patients and caregivers about potential side effects is an integral component of treatment and is important for a successful outcome 1 With the introduction of triple therapy, managing AEs due to Peg-IFN/RBV and AEs due to DAAs will become even more crucial to providing optimal care for patients DAA = Direct-acting antivirals 1. Ghany MG, et al. Hepatology 2009; 49: 1335
ةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationTreatment Initiation and Monitoring in HIV/HCV Co-infected Patients
Treatment Initiation and Monitoring in HIV/HCV Co-infected Patients Todd S. Wills, MD University of South Florida Hepatitis C Treatment Expansion Initiative Evaluation and Technical Assistance Center HCV
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationPretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationDECISION. Minister of Ministry of Health. Decides:
MINISTRY OF HEALTH ------- THE SOCIALIST REPUBLIC OF VIETNAM Independence Freedom Happiness --------------- Ref.: 4817/QĐ-BYT Ha Noi, November 28 th 2013 DECISION Issuance of technical guideline on HCV
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationHCVTreatment Process. Managementof HCV. StaQe 1- Surveillance and Education
Ii HCVTreatment Process Managementof HCV Hepatitis C virus infection represents a potentially serious problem within the correctional environment. It is widely recognized that Hepatitis C infection may
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationRecent Management of Chronic Hepatitis C
2014-6-12 KASL Liver Week 2014 Recent Management of Chronic Hepatitis C Jae-Jun Shim Kyung Hee University School of Medicine, Seoul, Korea Meeting today Cost and future perspectives Guidelines Recent guidelines
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationPRACTICE GUIDELINES INTRODUCTION
American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00754.x Published by Blackwell Publishing PRACTICE GUIDELINES Management and Treatment
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationGlobal Hepatitis Programme. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries
WHO/HIV/2014.26 World Health Organization 2014 Global Hepatitis Programme Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries WHO TECHNICAL REPORT
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationOver the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More information1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study
1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationThe medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationCHRONIC HCV TREATMENT: In Special Populations.
CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationReviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment
Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).
More informationBible Class: HCV Infection
Bible Class: HCV Infection PD Dr. Dr. med. Nasser Semmo UVCM, Hepatology What is the HCV prevalence and incidence? 2 HCV Prevalence Worldwide about 120-210 Mio. infected with HCV, about 9 Mio. in Europe,
More informationEASL Clinical Practice Guidelines: Management of hepatitis C virus infection
Clinical Practice Guidelines EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver Introduction Hepatitis C virus (HCV) infection
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationDisclosure. HBV Background
Disclosure I have the following financial relationships with the manufacturers of any commercial product(s) and/or provider of commercial services discussed in this CME activity: Research Support from:
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationAbstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4
Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov Abstract
More informationTreatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India
Original Article Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India 1 2 3 1 Omesh Goyal, Prerna Goyal, Deepinder Kaur, Rajoo Singh
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationAssessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More information